Qyuns Therapeutics Co., Ltd. Class H (HK:2509) has released an update.
Qyuns Therapeutics Co., Ltd. has announced its strategic move into wealth management by subscribing to various financial products with principal amounts totaling RMB210 million, across three major banks PDB, JSB, and ICBC. The subscriptions, which offer low-risk, principal-guaranteed floating yields, are expected to mature between June and July 2024. The company’s diversification into financial products signals a new avenue for growth and risk management.
For further insights into HK:2509 stock, check out TipRanks’ Stock Analysis page.
